Recent Analysts’ Ratings Changes for OptiNose (OPTN)

OptiNose (NASDAQ: OPTN) recently received a number of ratings updates from brokerages and research firms:

• 3/21/2025 – OptiNose had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $9.00 price target on the stock, down previously from $15.00.
• 3/21/2025 – OptiNose had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock, down previously from $18.00.
• 3/20/2025 – OptiNose was downgraded by analysts at Piper Sandler from a “strong-buy” rating to a “hold” rating.
• 3/20/2025 – OptiNose was downgraded by analysts at Lake Street Capital from a “buy” rating to a “hold” rating. They now have a $9.00 price target on the stock, down previously from $17.00.

OptiNose Stock Up 0.3 %

NASDAQ OPTN traded up $0.03 during trading on Monday, hitting $9.18. 41,782 shares of the stock traded hands, compared to its average volume of 60,385. The company has a market capitalization of $92.30 million, a P/E ratio of -2.19 and a beta of -0.30. OptiNose, Inc. has a 12-month low of $4.82 and a 12-month high of $24.60. The firm has a 50-day simple moving average of $5.96 and a 200-day simple moving average of $8.08.

Insider Activity at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now directly owns 126,931 shares of the company’s stock, valued at $671,464.99. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 8,213 shares of company stock valued at $43,643. 2.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new stake in OptiNose during the third quarter valued at approximately $61,000. State Street Corp increased its position in shares of OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after purchasing an additional 42,500 shares during the last quarter. Acorn Capital Advisors LLC bought a new stake in OptiNose in the fourth quarter worth $2,824,000. Geode Capital Management LLC boosted its stake in OptiNose by 33.7% during the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock worth $870,000 after buying an additional 326,918 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in OptiNose by 5.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock valued at $2,061,000 after acquiring an additional 155,329 shares during the last quarter. Institutional investors own 85.60% of the company’s stock.

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.